Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;10(Suppl 8):S910-S923.
doi: 10.21037/jtd.2018.02.85.

Machine perfusion of thoracic organs

Affiliations
Review

Machine perfusion of thoracic organs

Dirk Van Raemdonck et al. J Thorac Dis. 2018 Apr.

Abstract

This article summarizes recent knowledge and clinical advances in machine perfusion (MP) of thoracic organs. MP of thoracic organs has gained much attention during the last decade. Clinical studies are investigating the role of MP to preserve, resuscitate, and assess heart and lungs prior to transplantation. Currently, MP of the cardiac allograft is essential in all type DCD heart transplantation while MP of the pulmonary allograft is mandatory in uncontrolled DCD lung transplantation. MP of thoracic organs also offers an exciting platform to further investigate downregulation of the innate and adaptive immunity prior to reperfusion of the allograft in recipients. MP provides a promising technology that allows pre-transplant preservation, resuscitation, assessment, repair, and conditioning of cardiac and pulmonary allografts outside the body in a near physiologic state prior to planned transplantation. Results of ongoing clinical trials are awaited to estimate the true clinical value of this new technology in advancing the field of heart and lung transplantation by increasing the total number and the quality of available organs and by further improving recipient early and long-term outcome.

Keywords: Heart transplantation; donor after circulatory death; ex vivo lung perfusion (EVLP); lung transplantation; machine perfusion (MP).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: D Van Raemdonck was a principal investigator for the Inspire Trial and for the Expand Trial; both trials were sponsored by Transmedics® (Andover, MA, USA). F Rega receives research grants from Medtronic and is a consultant to Atricure Europe (Amsterdam, the Netherlands) and LivaNova Belgium (Zaventem, Belgium). The other authors have no conflicts of interest to declare.

Similar articles

Cited by

References

    1. Lund LH, Khush KK, Cherikh WS, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant 2017;36:1037-46. 10.1016/j.healun.2017.07.019 - DOI - PubMed
    1. Chambers DC, Yusen RD, Cherikh WS, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart-lung transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant 2017;36:1047-59. 10.1016/j.healun.2017.07.016 - DOI - PubMed
    1. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant 2016;35:1-23. 10.1016/j.healun.2015.10.023 - DOI - PubMed
    1. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015;34:1-15. 10.1016/j.healun.2014.06.014 - DOI - PubMed
    1. Messer S, Ardehali A, Tsui S. Normothermic donor heart perfusion: current clinical experience and the future. Transpl Int 2015;28:634-42. 10.1111/tri.12361 - DOI - PubMed

LinkOut - more resources